Docs shunning Avandia in wake of safety study

In another blow to GlaxoSmithKline, researchers say that Avandia's share of the market for newly prescribed oral anti-diabetics dropped from 10 percent to 0 percent in the two days after an NEJM study highlighting the drug's previously undisclosed safety risks. Most of those prescribers have evidently been shifting to Takeda's Actos, which saw an immediate surge in use. Shares of Glaxo took another hit on the news this morning. The swift market retribution took the analysts by surprise.

"This reaction is far worse than we had anticipated and suggests that there could be as much as 22 percent downside risk to GSK's near-term earnings, suggesting that there is still further downside to GSK's share price," according to analysis from Deutsche Bank.

- read the AP report on Avandia's numbers

ALSO: A new study by Northwest University's Charles Bennett, M.D., found that his group--RADAR--identified serious drug reactions six years earlier than the FDA and drug companies. Report

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.